Antitumour action of rhodium (I) and iridium (I) complexes

摘要: Abstract Several rhodium(I) and iridium(I) complexes displayed different degrees of antitumour activity when tested in mice bearing Ehrlich ascites carcinoma. Rhodium (I) iridium acetylacetonate derivatives caused a high percentage cures. The rhodium dimers were particularly interesting, since (bis(cycloocta-1,5-diene)μμ′dichlorodirhodium(I) [RhCODCl]2) was highly effective, whereas its analogues, bis(bicyclo[2,2,1]hepta-2,5-diene)μμ′-dichlorodirhodium(I) [RhNBDCl]2) bis(1,5-hexadiene)μμ′dichlorodirhodium(I) [RhEDCl]2) virtually inactive. absence significant inhibition DNA, RNA protein syntheses tumour cells found for [RhCODCl]2 at therapeutically active dosages, indicates that this substance has mechanism action from cis-dichlorodiammine Pt(II) (cis-PDD). amount after administration higher than [RhEDCl]2, while the concentration ascitic fluid much [RhEDCl]2. A based on chemical properties is tentatively proposed explaining these findings selective toxicity cells.